Biology of Childhood Osteogenic Sarcoma and Potential Targets for Therapeutic Development: Meeting Summary

Richard Gorlick; Peter Anderson; Irene Andrulis; Carola Arndt; G. Peter Beardsley; Mark Bernstein; Julia Bridge; Nai Kong Cheung; Jeffrey S. Dome; David Ebb; Thomas Gardner; Mark Gebhardt; Holcombe Grier; Marc Hansen; John Healey; Lee Helman; Janet Hock; Janet Houghton; Peter Houghton; Andrew Huvos; Chand Khanna; Mark Kieran; Eugenie Kleinerman; Marc Ladanyi; Ching Lau; David Malkin; Neyssa Marina; Paul Meltzer; Paul Meyers; Deborah Schofield; Cindy Schwartz; Malcolm A. Smith; Jeffrey Toretsky; Maria Tsokos; Leonard Wexler; Jon Wigginton; Stephen Withrow; Mason Schoenfeldt; Barry Anderson

Biology of Childhood Osteogenic Sarcoma and Potential Targets for Therapeutic Development: Meeting Summary

Richard Gorlick, Peter Anderson, Irene Andrulis, Carola Arndt, G. Peter Beardsley, Mark Bernstein, Julia Bridge, Nai Kong Cheung, Jeffrey S. Dome, David Ebb, Thomas Gardner, Mark Gebhardt, Holcombe Grier, Marc Hansen, John Healey, Lee Helman, Janet Hock, Janet Houghton, Peter Houghton, Andrew HuvosChand Khanna, Mark Kieran, Eugenie Kleinerman, Marc Ladanyi, Ching Lau, David Malkin, Neyssa Marina, Paul Meltzer, Paul Meyers, Deborah Schofield, Cindy Schwartz, Malcolm A. Smith, Jeffrey Toretsky, Maria Tsokos, Leonard Wexler, Jon Wigginton, Stephen Withrow, Mason Schoenfeldt, Barry Anderson

Pediatric and Adolescent Medicine

Research output: Contribution to journal › Article › peer-review

147 Scopus citations

Abstract

Childhood osteogenic sarcoma (OS) is a rare bone cancer occurring primarily in adolescents. The North American pediatric cooperative groups have performed a series of clinical treatment trials in this disease over the past several decades, and biology studies of tumor tissue have been an important study component. A meeting was held in Bethesda, Maryland on November 29-30, 2001, sponsored by the NIH Office of Rare Diseases, the Children's Oncology Group, and the National Cancer Institute-Cancer Therapy Evaluation Program with the general objectives: (a) to review the current state of knowledge regarding OS biology; (b) to identify, prioritize, and support the development of biology studies of potential clinical relevance in OS; and (c) to discuss the available tissue resources and the appropriate methods for analysis of OS samples for the conduct of biology studies. This report summarizes the information presented and discussed by the meeting participants.

Original language	English (US)
Pages (from-to)	5442-5453
Number of pages	12
Journal	Clinical Cancer Research
Volume	9
Issue number	15
State	Published - Nov 15 2003

ASJC Scopus subject areas

Oncology
Cancer Research

Cite this

Gorlick, R., Anderson, P., Andrulis, I., Arndt, C., Beardsley, G. P., Bernstein, M., Bridge, J., Cheung, N. K., Dome, J. S., Ebb, D., Gardner, T., Gebhardt, M., Grier, H., Hansen, M., Healey, J., Helman, L., Hock, J., Houghton, J., Houghton, P., ... Anderson, B. (2003). Biology of Childhood Osteogenic Sarcoma and Potential Targets for Therapeutic Development: Meeting Summary. Clinical Cancer Research, 9(15), 5442-5453.

Gorlick, R, Anderson, P, Andrulis, I, Arndt, C, Beardsley, GP, Bernstein, M, Bridge, J, Cheung, NK, Dome, JS, Ebb, D, Gardner, T, Gebhardt, M, Grier, H, Hansen, M, Healey, J, Helman, L, Hock, J, Houghton, J, Houghton, P, Huvos, A, Khanna, C, Kieran, M, Kleinerman, E, Ladanyi, M, Lau, C, Malkin, D, Marina, N, Meltzer, P, Meyers, P, Schofield, D, Schwartz, C, Smith, MA, Toretsky, J, Tsokos, M, Wexler, L, Wigginton, J, Withrow, S, Schoenfeldt, M & Anderson, B 2003, 'Biology of Childhood Osteogenic Sarcoma and Potential Targets for Therapeutic Development: Meeting Summary', Clinical Cancer Research, vol. 9, no. 15, pp. 5442-5453.

@article{75ba26a39a804a74bcdfcb8dd1c2e39c,

title = "Biology of Childhood Osteogenic Sarcoma and Potential Targets for Therapeutic Development: Meeting Summary",

abstract = "Childhood osteogenic sarcoma (OS) is a rare bone cancer occurring primarily in adolescents. The North American pediatric cooperative groups have performed a series of clinical treatment trials in this disease over the past several decades, and biology studies of tumor tissue have been an important study component. A meeting was held in Bethesda, Maryland on November 29-30, 2001, sponsored by the NIH Office of Rare Diseases, the Children's Oncology Group, and the National Cancer Institute-Cancer Therapy Evaluation Program with the general objectives: (a) to review the current state of knowledge regarding OS biology; (b) to identify, prioritize, and support the development of biology studies of potential clinical relevance in OS; and (c) to discuss the available tissue resources and the appropriate methods for analysis of OS samples for the conduct of biology studies. This report summarizes the information presented and discussed by the meeting participants.",

author = "Richard Gorlick and Peter Anderson and Irene Andrulis and Carola Arndt and Beardsley, {G. Peter} and Mark Bernstein and Julia Bridge and Cheung, {Nai Kong} and Dome, {Jeffrey S.} and David Ebb and Thomas Gardner and Mark Gebhardt and Holcombe Grier and Marc Hansen and John Healey and Lee Helman and Janet Hock and Janet Houghton and Peter Houghton and Andrew Huvos and Chand Khanna and Mark Kieran and Eugenie Kleinerman and Marc Ladanyi and Ching Lau and David Malkin and Neyssa Marina and Paul Meltzer and Paul Meyers and Deborah Schofield and Cindy Schwartz and Smith, {Malcolm A.} and Jeffrey Toretsky and Maria Tsokos and Leonard Wexler and Jon Wigginton and Stephen Withrow and Mason Schoenfeldt and Barry Anderson",

year = "2003",

month = nov,

day = "15",

language = "English (US)",

volume = "9",

pages = "5442--5453",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "15",

}

TY - JOUR

T1 - Biology of Childhood Osteogenic Sarcoma and Potential Targets for Therapeutic Development

T2 - Meeting Summary

AU - Gorlick, Richard

AU - Anderson, Peter

AU - Andrulis, Irene

AU - Arndt, Carola

AU - Beardsley, G. Peter

AU - Bernstein, Mark

AU - Bridge, Julia

AU - Cheung, Nai Kong

AU - Dome, Jeffrey S.

AU - Ebb, David

AU - Gardner, Thomas

AU - Gebhardt, Mark

AU - Grier, Holcombe

AU - Hansen, Marc

AU - Healey, John

AU - Helman, Lee

AU - Hock, Janet

AU - Houghton, Janet

AU - Houghton, Peter

AU - Huvos, Andrew

AU - Khanna, Chand

AU - Kieran, Mark

AU - Kleinerman, Eugenie

AU - Ladanyi, Marc

AU - Lau, Ching

AU - Malkin, David

AU - Marina, Neyssa

AU - Meltzer, Paul

AU - Meyers, Paul

AU - Schofield, Deborah

AU - Schwartz, Cindy

AU - Smith, Malcolm A.

AU - Toretsky, Jeffrey

AU - Tsokos, Maria

AU - Wexler, Leonard

AU - Wigginton, Jon

AU - Withrow, Stephen

AU - Schoenfeldt, Mason

AU - Anderson, Barry

PY - 2003/11/15

Y1 - 2003/11/15

N2 - Childhood osteogenic sarcoma (OS) is a rare bone cancer occurring primarily in adolescents. The North American pediatric cooperative groups have performed a series of clinical treatment trials in this disease over the past several decades, and biology studies of tumor tissue have been an important study component. A meeting was held in Bethesda, Maryland on November 29-30, 2001, sponsored by the NIH Office of Rare Diseases, the Children's Oncology Group, and the National Cancer Institute-Cancer Therapy Evaluation Program with the general objectives: (a) to review the current state of knowledge regarding OS biology; (b) to identify, prioritize, and support the development of biology studies of potential clinical relevance in OS; and (c) to discuss the available tissue resources and the appropriate methods for analysis of OS samples for the conduct of biology studies. This report summarizes the information presented and discussed by the meeting participants.

AB - Childhood osteogenic sarcoma (OS) is a rare bone cancer occurring primarily in adolescents. The North American pediatric cooperative groups have performed a series of clinical treatment trials in this disease over the past several decades, and biology studies of tumor tissue have been an important study component. A meeting was held in Bethesda, Maryland on November 29-30, 2001, sponsored by the NIH Office of Rare Diseases, the Children's Oncology Group, and the National Cancer Institute-Cancer Therapy Evaluation Program with the general objectives: (a) to review the current state of knowledge regarding OS biology; (b) to identify, prioritize, and support the development of biology studies of potential clinical relevance in OS; and (c) to discuss the available tissue resources and the appropriate methods for analysis of OS samples for the conduct of biology studies. This report summarizes the information presented and discussed by the meeting participants.

UR - http://www.scopus.com/inward/record.url?scp=0344198135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344198135&partnerID=8YFLogxK

M3 - Article

C2 - 14654523

AN - SCOPUS:0344198135

SN - 1078-0432

VL - 9

SP - 5442

EP - 5453

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 15

ER -

Biology of Childhood Osteogenic Sarcoma and Potential Targets for Therapeutic Development: Meeting Summary

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this